G roup IIA secretory nonpancreatic phospholipase A 2 (snpPLA 2 ) is a 14-kDa calcium-dependent enzyme that hydrolyzes the sn-2 fatty acid acyl ester bond of phosphoglycerides to free fatty acids (FFAs) and lysophospholipids. 1 These products can act as intracellular second messengers or be further metabolized into proinflammatory lipid mediators. 2 Immunohistochemical studies demonstrated the presence of snpPLA 2 in human arteries, 3 and ultrastructural localization showed that some of the snpPLA 2 was located along collagen fibers in the extracellular matrix of human atherosclerotic lesions. 4 Most of the collagen in arterial intima is collagen types I and III. Interspersed between these is collagen type VI, which appears in all vascular layers. 5 Several studies have shown that collagen interacts with decorin, a chondroitin/ dermatan sulfate (CS/DS) proteoglycan (PG) of the SLRP family class I. 6, 7 Decorin is present in the arterial wall, and its distribution is different in healthy arteries from that of atherosclerotic plaques. 8 When decorin is associated with collagen, both the core protein and the glycosaminoglycan (GAG) chain are still available for binding to other ligands, eg, transforming growth factor (TGF)-␤ 9 and LDL. 10 These observations suggest that some of the extracellular snpPLA 2 detected in the arterial intima of lesions may be associated with collagen fibers via its interaction with decorin.
The hypothesis of the potential involvement of snpPLA 2 in the pathogenesis of atherosclerosis 11 was recently reinforced with in vivo data. [12] [13] [14] The proatherogenic mechanisms of snpPLA 2 may be potentiated by the capacity of both snpPLA 2 and apolipoprotein (apo) B lipoproteins to interact with sulfated PG/GAG. 15 This may be a mechanism that contributes to colocalization of the enzyme and lipoproteins at cell membranes and extracellular space. However, the molecular basis for the interactions of snpPLA 2 with extracellular matrix components and how this may locate and control enzyme activity at sites of lesion development needs to be clarified. In the present work, we performed immunohistochemistry to explore the relative distribution of decorin and snpPLA 2 in human nonatherosclerotic and atherosclerotic tissue. We also studied, in vitro, the binding of snpPLA 2 to decorin, the role of decorin in mediating the binding of snpPLA 2 to collagen types I and VI, and how decorin modulates snpPLA 2 activity.
Materials and Methods

Immunohistochemistry
Human carotid artery segments were obtained from autopsy or surgery and quickly frozen and stored at Ϫ20°C until sectioning. Uterine arteries (used as nonatherosclerotic control tissue) were obtained from women undergoing hysterectomy. Atherosclerotic regions were defined by the presence of intima thickness accompanied by extracellular lipid accumulations, cholesterol crystals, and foam-cell and non-foam-cell macrophages.
Immunofluorescence staining was performed on atherosclerotic (nϭ9) and nonatherosclerotic (nϭ4) arteries. 3 Mouse monoclonal antibody (mAb) BF1 was used to detect snpPLA 2 . An antibody generated against smooth muscle cell actin, HHF-35, recognized vascular smooth muscle cells. Decorin was detected by an mAb generated against the core protein moiety. 16 In addition, some sections were incubated with or without chondroitinase ABC (ChABC). Standard hematoxylin/eosin staining for routine histological evaluation of the sections was also performed.
Isolation and Characterization of PG
Confluent human skin fibroblasts maintained in Eagle's minimum essential medium in bottles coated with collagen type I 17 were incubated for 3 days with medium containing L- [4,5- 3 H]leucine and [
35 S]sulfur at final specific activities of 17 Ci/mL and 33 Ci/mL, respectively. Conditioned medium was collected and supplemented with protease inhibitors. PGs, isolated from conditioned medium, 18 were digested with chondroitinase AC (ChAC), chondroitinase B (ChB), or heparitinase I (HS I) and analyzed by SDS-PAGE. 19 PGs were also digested with ChABC, and Western blot was performed essentially as described. 18 In Vitro Interactions of snpPLA 2 With Decorin and Collagen snpPLA 2 was purified from conditioned medium from a transfected CHO cell line 20 as described. 21 Binding of snpPLA 2 to fibroblastderived PG was analyzed by electrophoretic mobility shift assay (EMSA). 22 Expression and purification of a recombinant decorin core protein fragment representing Asp45-Lys359 (B/E) was done essentially as described. 23 Microtiter wells were coated with collagen type I or VI or FFA-free BSA. 6 Native decorin (from bovine articular cartilage) or decorin digested with ChABC was added to some wells. Nonbound decorin was determined in the supernatants after incubation. 24 snpPLA 2 was diluted with D-PBS and added to the wells in increasing concentrations. After incubation, the activity of bound snpPLA 2 was determined by measuring generation of FFA from PC mixed micelles (prepared as described below) with a commercial kit (NEFA-C).
Microtiter wells were coated with the B/E fragment. In some experiments, snpPLA 2 was added directly to the B/E-coated wells. In a second set of experiments, a constant concentration of snpPLA 2 (290 nmol/L) was mixed with increasing concentrations of decorin before it was added to the B/E-coated wells. In a third set of experiments, snpPLA 2 (290 nmol/L) was added to B/E-coated wells in D-PBS supplemented with NaCl. In all experiments, the activity of snpPLA 2 retained in the B/E-coated wells was determined as described above.
snpPLA 2 Activity
PC mixed micelles were prepared as described. 21 Human LDL was isolated from healthy fasted male volunteers. 25 snpPLA 2 and decorin or GAG-depleted decorin were preincubated (30 minutes, room temperature) before substrate was added. snpPLA 2 activity was determined by measuring release of FFA during the incubations.
An expanded Materials and Methods section is available online at http://www.circresaha.org. 
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Results
Immunohistochemistry
The selectivity of the mAb generated against decorin was initially tested and confirmed on sections of normal human skin segments (data not shown). In human nonatherosclerotic arteries ( Figure 1 ), prominent staining of decorin was detected by immunofluorescence only in the adventitia. In sections of atherosclerotic lesions ( Figure 2 ) showing a thickened intima and part of the media, decorin was detected mainly in the layer of intima close to the media and less in the subendothelial part of the intima, as shown in Figure 2A and Figure 2E and 2F). On the basis of their morphology and findings from earlier studies, these additional cells may be macrophages. 3 In advanced atherosclerotic lesions (Figure 3 ), decorin was detected in the plaque core close to the media overlapping with snpPLA 2 staining. Some atherosclerotic sections were also preincubated with ChABC before immunostaining was performed (see online supplementary information; http://www.circresaha. org). In brief, the immunohistological detection of snpPLA 2 increased after ChABC treatment in regions corresponding to areas that also stain positive for decorin. This suggests that the removal of the GAG moiety unmasks but does not remove snpPLA 2 -antigen associated with decorin. A summary of the immunohistological detection of decorin and snpPLA 2 is presented in the Table. The extent of decorin distribution in intima corresponds with severity of the lesion and coincides with snpPLA 2 staining, except that more areas are positive for snpPLA 2 than decorin.
Isolation and Characterization of PG
Decorin is a quiescence-inducible gene in fibroblasts, 26 and reverse transcription-polymerase chain reaction evaluation of total RNA isolated from the cells indicated a high expression of decorin 1 to 7 days postconfluence (data not shown). The PG preparation obtained from conditioned medium contained mainly decorin ( Figure 4A and 4B). The band migrating at Ϸ100 kDa was totally degraded by ChB, indicating the presence of DS. A protein band with a molecular weight of 45 to 50 kDa, corresponding to the size of the core protein of decorin, was left after digestion with ChB, and it was identified as the decorin core protein by Western blot analysis. The PG preparation also contained a small proportion of a material retained at the top of the gel that was susceptible to HS I digestion (perlecan-like).
In Vitro Interactions of snpPLA 2 With Decorin and Collagen
We studied the interaction of snpPLA 2 with decorin and with decorin bound to collagen type I or VI in 2 different in vitro models: (1) EMSA with decorin isolated from human fibroblasts and (2) a solid-phase binding assay using collagen and collagen-decorin-coated microtiter wells.
In the EMSA assay ( Figure 4C ), the intensity of the band corresponding to free decorin decreases in the presence of 0.25 mol/L of snpPLA 2 and also with 0.5 mol/L of snpPLA 2 . Furthermore, the band corresponding to decorin migrates differently and becomes wider in the presence of 0.5 mol/L of snpPLA 2 compared with the control (without snpPLA 2 ). At concentrations Ͼ1 mol/L of snpPLA 2 , there is no free decorin, and all decorin molecules have formed complexes with snpPLA 2 and remain at the origin of the gel. These results indicate that snpPLA 2 binds to decorin in vitro at physiological ionic conditions.
The possibility that decorin may serve as a link between collagen fibers and snpPLA 2 was investigated with a microtiter-well binding assay. The wells were first coated with collagen type I or VI, and then decorin was added. The wells coated with collagen type VI bound more decorin (370Ϯ50 ng, nϭ9) than the wells coated with collagen type I (160Ϯ60 ng, nϭ16). Control wells contained either collagen type I or VI or BSA. Measuring snpPLA 2 activity monitored binding of snpPLA 2 . snpPLA 2 did not bind to the wells coated only with collagen type I or with BSA ( Figure 5A ). However, snpPLA 2 was able to bind to collagen type VI ( Figure 5B ). The binding to collagen type VI was higher than that of control wells coated with BSA. This suggests that snpPLA 2 may associate with collagen type VI even in the absence of decorin. Interestingly, the addition of decorin to collagen-coated wells significantly enhanced the binding of active snpPLA 2 to both collagen types I and VI ( Figure 5A and 5B), indicating that decorin may mediate binding of snpPLA 2 to collagen fibers. snpPLA 2 may bind to decorin through the GAG and/or the protein moiety of the PG. To discriminate between these possibilities, we performed experiments with decorin and decorin pretreated with ChABC. There was no difference in the amount of active snpPLA 2 binding to untreated decorin or GAG-depleted decorin in plates coated with collagen type VI ( Figure 5C ). Importantly, the GAG moiety in decorin was totally degraded, according to analysis of ChABC-treated decorin by SDS-PAGE (data not shown). These results suggest that snpPLA 2 binds to GAG-depleted decorin, possibly through a direct interaction with the core protein of decorin. Notably, in similar experiments performed with versican-coated plates, the retention of active snpPLA 2 decreased significantly after GAG digestion (see online supplementary information; http://www.circresaha.org).
To further analyze the binding of snpPLA 2 to the core protein of decorin, a recombinant core protein fragment of human decorin, Asp45-Lys359 (fragment B/E), was expressed. Compared with the complete processed and secreted decorin core protein, this fragment lacks 14 amino acid residues at the N-terminal, it carries no GAG chain, and it is not glycosylated. snpPLA 2 was efficiently retained in B/Ecoated wells ( Figure 6A ). The wells contained 910Ϯ430 ng (nϭ9) of the B/E fragment. The binding to the BSA-coated wells was low. It was possible to compete the binding of snpPLA 2 to immobilized B/E by soluble decorin (Figure 6B ). At the highest concentration of competitor (0.2 g/L), only Ϸ20% of the snpPLA 2 was bound, compared with 100% snpPLA 2 bound in the absence of competitor. The binding of snpPLA 2 to B/E-coated wells appears to be mediated mainly by electrostatic interactions, because the binding was almost completely inhibited by increasing the NaCl concentration up to 1 mol/L in the binding buffer ( Figure 6C ).
Experiments were also performed with decorin-coated microtiter wells using the B/E fragment or DS as competitors. The B/E fragment was more efficient in competing for binding of snpPLA 2 to decorin-coated wells compared with DS. Preincubation of 290 nmol/L snpPLA 2 together with 0.12 g/L of B/E (M w Ϸ35 kDa) or DS (M w 11 to 25 kDa) reduced the binding of snpPLA 2 to the decorin-coated wells Figure 4 . A, PGs isolated from conditioned fibroblast culture media were digested with ChAC, ChB, HS I, or without enzyme (Ctrl) and analyzed by 4% to 12% SDS-PAGE. Radioactive bands were visualized by autoradiography (Std, molecular weight standards). Arrow indicates the remaining core protein of decorin. B, Western blot. An aliquot of the PG preparation was digested with ChABC and separated on a 4% to 12% SDS-PAGE. After transfer, the membrane was developed with an ECLϩPlus Western blotting detection system using polyclonal antibodies against human decorin. C, EMSA. A constant amount of PG was incubated with increasing concentrations of snpPLA 2 (as indicated). The PG-protein complexes were separated from free PG by agarose-gel electrophoresis. The radioactive bands were visualized by autoradiography. Results are representative for an experiment performed twice. Atherosclerotic lesions (nϭ5)
Presence of moderate staining is indicated with ϩ, very intense staining is indicated with ϩϩ, and the absence of staining is indicated with Ϫ.
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to 40% (B/E) and 90% (DS), compared with 100% binding in the absence of competitors. Ten times higher concentrations of the competitors further reduced the binding of snpPLA 2 to the decorin-coated wells to 18% and 70%, respectively.
Effect of Decorin on the Activity of snpPLA 2
To investigate whether the interaction with decorin could affect the enzyme activity, increasing concentrations of decorin or GAG-depleted decorin were incubated with snpPLA 2 . snpPLA 2 activity was increased in the presence of decorin when PC micelles or LDL was used as substrate presenting structures (Figure 7) . Interestingly, a similar enhancing effect on snpPLA 2 activity was observed with untreated decorin and with GAG-depleted decorin. These results support the results from the microtiter binding assay indicating that snpPLA 2 binds to the core protein of decorin and that this interaction enhances snpPLA 2 activity.
Discussion snpPLA 2 displays 3 biochemical properties of a secretory enzyme. First, the cDNA encodes a 144-amino-acid protein including a 20-amino-acid signal peptide. Second, snpPLA 2 has 7 disulfide bridges, which makes it a very stable protein against proteolysis and nonenzymatic hydrolysis. Third, it requires millimolar concentrations of calcium for its activity. Microtiter wells were coated with collagen type I (A) or VI (B) or FFA-free BSA and then incubated with or without decorin. snpPLA 2 was added in increasing concentrations (x axis). The activity of bound snpPLA 2 was determined by measuring the release of FFA from PC mixed micelles. C, Microtiter wells were coated with collagen VI and then incubated with decorin or ChABC-treated decorin. snpPLA 2 was added in increasing concentrations (x axis). The activity of bound snpPLA 2 was determined as indicated above. Data presented are meanϮSD of 3 independent incubations for each representative experiment. Figure 6 . Microtiter wells were coated with the decorin core protein fragment B/E or FFA-free BSA. A, Increasing concentrations of snpPLA 2 (x axis) was added to the wells. The activity of bound snpPLA 2 was determined as described in Figure 5 . B, Competition of snpPLA 2 binding to B/E-coated wells by soluble decorin. Decorin in increasing concentrations (x axis) was added together with snpPLA 2 (290 nmol/L). The activity of bound snpPLA 2 in the absence of competitor was set at 100%. C, Effect of NaCl concentration on the binding of snpPLA 2 to B/Ecoated wells. snpPLA 2 (290 nmol/L) was added to the wells in D-PBS supplemented with NaCl (x axis). The activity of bound snpPLA 2 in D-PBS was set at 100%. Data presented are meanϮSD of 3 independent incubations for each representative experiment.
The immunofluorescence results in the present study show that staining for snpPLA 2 coincides with regions that stain positively for the extracellular matrix PG decorin in human atherosclerotic arteries. The distribution of decorin and snpPLA 2 in nonatherosclerotic and atherosclerotic arteries was similar to what has been reported. 3, 8, 27 The immunofluorescence results on arterial wall sections indicate colocalization of snpPLA 2 and decorin. However, the relative differences of the signal intensities suggest that other matrix components besides collagen-associated decorin may also bind snpPLA 2 . Hence, the presence of extracellular snpPLA 2 is not dependent on decorin, because snpPLA 2 shows a wider distribution pattern than decorin. Decorin is one of the several PGs known to accumulate in human atherosclerotic plaques, and it colocalizes with collagen. 27 Its major functions appear to be assembly of collagen fibers, binding and regulation of growth factor activity, and control of cell growth. 7 Decorin possesses 2 main collagenbinding sites 23 that do not involve the CS/DS moiety. The single GAG chain located at Ser7 close to the N-terminal of the core protein protrudes away from decorin and is free to interact with other proteins. The results obtained in this work with 2 different in vitro binding assays show that snpPLA 2 is able to interact with both the GAG moiety and the core protein of decorin at physiological salt and pH conditions. The mobility of decorin in the EMSA experiments, in which snpPLA 2 was present in large excess, was inhibited, suggesting interaction with the GAG side chain. The mobility of the PG in the gel electrophoresis is dependent on its negatively charged GAG. Association of the snpPLA 2 with the GAG appeared to be responsible for the inhibited mobility. However, the solid-phase binding assay, in which decorin and snpPLA 2 were present in similar amounts, showed that snpPLA 2 also binds to GAG-depleted decorin. These results were confirmed with experiments performed with a human recombinant decorin core protein fragment (Asp45-Lys359). Furthermore, this fragment competed more efficiently than DS for snpPLA 2 binding to immobilized decorin, indicating a higher affinity of snpPLA 2 for the decorin core protein fragment compared with the DS side chain. Taken together, these results indicate that snpPLA 2 preferentially binds to the core protein of decorin. Other proteins, such as TGF-␤ and apoB, 9, 10 have also been shown to interact with collagenbound decorin.
Versican, a high-molecular-weight interstitial CS-rich PG, is abundant in the arterial intima and accumulates especially in the early phase of lesion development. 5 Previous studies have shown that versican isolated from human arterial smooth muscle cell binds to snpPLA 2 in vitro mainly via the GAG moiety. 21 The results presented in this study support this observation, and degradation of the GAG reduced the capacity of immobilized versican to bind exogenous snpPLA 2 . There are regional differences in the distribution of decorin and versican in the normal and atherosclerotic arterial wall, suggesting that these PGs may have different functional roles during lesion progression. 8 Decorin increased the enzymatic activity of snpPLA 2 independently if the substrate presenting structure was LDL or PC micelles. LDL is known to bind to GAG of arterial PG, a process considered to be a key event in atherogenesis. 28, 29 Interestingly, decorin was reported to link LDL and collagen fibers in vitro through its CS/DS chain. 10 In addition, apo(a) from Lp(a) binds to the core protein of decorin. 30 These findings suggest that binding of snpPLA 2 and apoBcontaining lipoproteins to CS/DS PGs may facilitate their colocalization in the arterial intima. This may enhance the hydrolysis of phospholipids at places of apoB lipoprotein deposition in the arterial wall.
The levels of extracellular snpPLA 2 appear to be regulated through both secretion of already synthesized enzyme and modulation of its gene expression. Inflammatory cytokines, including interleukin (IL)-1␤ and tumor necrosis factor-␣, are reported to stimulate the secretion of snpPLA 2 . 31, 32 In contrast, TGF-␤ and platelet-derived growth factor are reported to inhibit snpPLA 2 expression. 33 Furthermore, these cytokines and growth factors are reported to modulate the expression of different PGs by arterial smooth muscle cells. 34 Interestingly, the expression of snpPLA 2 and decorin is regulated similarly by IL-1␤ and TGF-␤. These findings suggest that the distribution of snpPLA 2 and decorin in the arterial wall may be modulated by local inflammatory conditions characteristic for atherogenesis. 35 As a consequence, one may also expect modulation of the local activity of extracellular snpPLA 2 in the arterial wall by the cytokines.
Taken together, these data suggest that PGs known to accumulate in atherosclerosis 8 might bind snpPLA 2 secreted by smooth muscle cells and thereby be partially responsible for the abundant extracellular snpPLA 2 detected in arterial plaques, 3, 4 thus reinforcing the hypothesis that the presence of active extracellular snpPLA 2 in the arterial wall may contribute to lipoprotein modification and generation of lipid mediators at places of atherosclerotic plaque formation and progression. Figure 7 . snpPLA 2 was mixed with increasing concentrations of decorin (before or after GAG depletion) as indicated on the x axis. PC mixed micelles or LDL was added to each reaction, and the samples were incubated at 37°C. The enzyme activity was determined by measurement of production of FFA. Data presented are meanϮSD of 3 independent incubations for each representative experiment.
